文摘
摘要目的:以确定可溶性ST2 (sST2)与神经毒性后嵌合抗原受体t细胞(CAR-T)治疗。
背景:sST2属于已知受体家族预测结果缺血性及出血性中风。其神经毒性作用后CAR-T疗法尚未报道。
设计/方法:sST2浓度测定血浆样品从一群43病人CAR-T注入淋巴瘤丹纳-法伯癌症研究中心的研究。血液是在基线和输液后7天。sST2测量使用商业化ELISA(关键诊断,圣地亚哥,CA)。神经毒性被定义为1级或更常见的不良事件的术语标准评定量表。sST2和神经毒性之间的关系确定使用逻辑回归和接收方操作曲线(ROC)分析。斯皮尔曼等级相关被用来确定sST2水平之间的关系和速度经颅多普勒(tcd)。
结果:神经毒性的患者有类似水平的sST2基线,但高水平在7天(100.9 ng / mL(差49.7—-200)和47.1 (30.4 - -58.8),p = 0.02)。ROC分析表明sST2 > 80.0 ng / mL神经毒性预测曲线下面积为0.657。协变量调整后临床,sST2仍是一个独立的预测因子神经毒性与年龄和c反应蛋白最终模型。血清白介素6与sST2共线模型,和两个显著相关(ρ= 0.71,p < 0.0005)。最后,sST2水平被发现与峰值MCA, PCA, ACA TCD速度(MCAρ= 0.73,p < 0.005;PCAρ= 0.83,p < 0.0001;ACAρ= 0.74,p < 0.001)。
结论:等离子体后速度与神经毒性和TCD sST2汽车t细胞疗法。这些结果支持的角色sST2神经与血管的损伤的生物标志物。
披露:Fietsam小姐没有披露。部女士没有披露。Booraem女士没有披露。琼斯女士没有披露。金伯利博士已经收到个人薪酬在10000 - 49999美元的范围作为顾问NControl疗法。金伯利博士已经收到个人薪酬在500 - 4999美元的范围作为一个编辑,副主编,为神经病治疗或编辑顾问委员会成员。金伯利博士伍尔西制药公司的股票。金伯利博士的机构收到生原体的研究支持。金伯利博士的机构收到NControl疗法的研究支持。金伯利博士的机构收到NIH的研究支持。 The institution of Dr. Kimberly has received research support from American Heart Association. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care. Dr. Jacobson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Kite/Gilead. Dr. Jacobson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BMS/Celgene. Dr. Jacobson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for bluebird bio. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epizyme. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Instil Bio. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abintus Bio. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Caribou Bio. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Miltenyi. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Morphosys. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazeneca. Dr. Jacobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ImmPACT Bio. Dr. Jacobson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for CRICO. Dr. Jacobson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Weitz and Lutz. The institution of Dr. Jacobson has received research support from Kite/Gilead. The institution of Dr. Jacobson has received research support from Pfizer. Dr. Bevers has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for EBSCO. An immediate family member of Dr. Bevers has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Hinshaw Law. An immediate family member of Dr. Bevers has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Colorado Department of Law. The institution of Dr. Bevers has received research support from NINDS. The institution of an immediate family member of Dr. Bevers has received research support from AHRQ. The institution of Dr. Bevers has received research support from AAN. The institution of an immediate family member of Dr. Bevers has received research support from VIIV. The institution of an immediate family member of Dr. Bevers has received research support from NIH/Kowa Industries.
